Schering-Plough 4Q Revenues: $4.3 billion (+17%) 4Q Earnings: $480 million (loss of $3.3 billion in 4Q07) FY Revenues: $18.5 billion (+46%) FY Earnings: $1.6 billion (loss of $1.6 billion FY07) Comments: Sales of Remicade were $491 million in the quarter (+8%) and $2.1 billion for the year (+28%). Sales of Temodar were up 4% to $242 million in the quarter and $1.0 billion for the year (+16%). Global sales of Nasonex were $280 million in the quarter (+3%) and $1.2 billion for the y...